Free Trial

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular logo
$92.12 -0.13 (-0.14%)
(As of 12/20/2024 05:16 PM ET)

LeMaitre Vascular - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
7

Based on 9 Wall Street analysts who have issued ratings for LeMaitre Vascular in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for LMAT.

Consensus Price Target

$94.57
2.66% Upside
According to the 9 analysts' twelve-month price targets for LeMaitre Vascular, the average price target is $94.57. The highest price target for LMAT is $105.00, while the lowest price target for LMAT is $75.00. The average price target represents a forecasted upside of 2.66% from the current price of $92.12.
Get the Latest News and Ratings for LMAT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LeMaitre Vascular and its competitors.

Sign Up

LMAT Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$94.57$94.57$94.40$67.60
Forecasted Upside2.66% Upside-10.67% Downside4.94% Upside18.74% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

LMAT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LMAT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

LeMaitre Vascular Stock vs. The Competition

TypeLeMaitre VascularMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.66% Upside25,828.56% Upside14.54% Upside
News Sentiment Rating
Positive News

See Recent LMAT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/1/2024Oppenheimer
3 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$90.00 ➝ $93.00-6.96%
11/1/2024Barrington Research
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$92.00 ➝ $93.00-7.01%
10/15/2024Cantor Fitzgerald
4 of 5 stars
R. Osborn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$96.00+4.19%
8/20/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform ➝ Market Outperform$77.00 ➝ $100.00+16.92%
8/2/2024Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$85.00 ➝ $105.00+20.73%
5/31/2024Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wittes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/31/2024Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$100.00+26.95%
4/26/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$59.00 ➝ $75.00+19.07%
2/6/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Weight
8/3/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$63.00 ➝ $67.00+3.55%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:37 AM ET.


LMAT Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for LeMaitre Vascular is $94.57, with a high forecast of $105.00 and a low forecast of $75.00.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LMAT shares.

According to analysts, LeMaitre Vascular's stock has a predicted upside of 2.66% based on their 12-month stock forecasts.

LeMaitre Vascular has been rated by research analysts at Barrington Research, Cantor Fitzgerald, and Oppenheimer in the past 90 days.

Analysts like LeMaitre Vascular more than other "medical" companies. The consensus rating score for LeMaitre Vascular is 2.89 while the average consensus rating score for "medical" companies is 2.81. Learn more on how LMAT compares to other companies.


This page (NASDAQ:LMAT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners